Humoral immunity to HIV, SIV, and SHIV

Optimized protocol for detection of native, full-length HIV-1 envelope on the surface of transfected cells.

Health science reports·2019

B cells in the pathogenesis of AIDS.

Immunology today·2014

Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Mucosal immunology·2013

Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.

Journal of virology·2006

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.

Journal of virology·2006

Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques.

Journal of virology·2005

Circulating markers of organ damage associate with COPD in people with HIV: an exploratory proteomic analysis.

AIDS (London, England)·2026

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.

AIDS (London, England)·2026

Sex-modulated associations between cytomegalovirus cell-associated DNA and cognition in people with HIV on ART.

AIDS (London, England)·2026

Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV.

AIDS (London, England)·2026

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations.

AIDS (London, England)·2026

Comparing carbon emissions from oral tenofovir disoproxil fumarate/emtricitabine for preexposure prophylaxis and long-acting injectables for HIV prevention.

AIDS (London, England)·2026

Interleukin-39 aggravates sepsis by inducing self-sustaining neutrophil activation in the lungs via the CXCL1-CXCR2 pathway.

International journal of biological sciences·2026

Mechanisms and clinical research progress of IL-6-mediated crosstalk between the alveolar microenvironment and the immune system in patients with severe pneumonia undergoing mechanical ventilation.

Frontiers in immunology·2026

Roles of IL-34 in neurological diseases: neuroprotection, inflammatory regulation, and myeloid plasticity.

Frontiers in immunology·2026

Inflammatory remodeling of the ovarian microenvironment in premature ovarian insufficiency: mechanisms and therapeutic opportunities.

Frontiers in immunology·2026

Recent understanding of immunometabolic remodeling in pulmonary macrophages: homeostasis, chronic respiratory diseases, and therapeutic targeting.

Frontiers in pharmacology·2026

RAC2 orchestrates immune cell actin remodeling and migration.

Frontiers in immunology·2026

Related Experiment Videos

Humoral immunity to HIV, SIV, and SHIV

Related Concept Videos

Optimized protocol for detection of native, full-length HIV-1 envelope on the surface of transfected cells.

B cells in the pathogenesis of AIDS.

Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.

Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques.

Circulating markers of organ damage associate with COPD in people with HIV: an exploratory proteomic analysis.

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.

Sex-modulated associations between cytomegalovirus cell-associated DNA and cognition in people with HIV on ART.

Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV.

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations.

Comparing carbon emissions from oral tenofovir disoproxil fumarate/emtricitabine for preexposure prophylaxis and long-acting injectables for HIV prevention.

Interleukin-39 aggravates sepsis by inducing self-sustaining neutrophil activation in the lungs via the CXCL1-CXCR2 pathway.

Mechanisms and clinical research progress of IL-6-mediated crosstalk between the alveolar microenvironment and the immune system in patients with severe pneumonia undergoing mechanical ventilation.

Roles of IL-34 in neurological diseases: neuroprotection, inflammatory regulation, and myeloid plasticity.

Inflammatory remodeling of the ovarian microenvironment in premature ovarian insufficiency: mechanisms and therapeutic opportunities.

Recent understanding of immunometabolic remodeling in pulmonary macrophages: homeostasis, chronic respiratory diseases, and therapeutic targeting.

RAC2 orchestrates immune cell actin remodeling and migration.

Related Experiment Videos

Humoral immunity to HIV, SIV, and SHIV

Related Concept Videos

Related Articles